The new ‘Life Sciences platform’ serves as a strong addition to Gimv’s four existing investment platforms: Sustainable Cities, Smart Industries, Consumer and Healthcare. It will enable the company “to build on the strong track record of Gimv in life sciences investments,” comments Gimv CEO Koen Dejonckheere. 

The company’s track record includes excellent returns on investments generated by a variety of portfolio companies over four decades, including Flanders-based biopharma firm Ablynx, in which Gimv was a founding investor, and Covagen, a biotech company acquired by Johnson & Johnson. 

In addition, the new platform enables Gimv to further strengthen its capacity to invest in larger “tickets”. Consequently, initial investments going forward will typically amount to between EUR 10 million and EUR 15 million per company. 

Aiming to virtually double its current portfolio, Gimv will retain its Series A and B investment strategies with a particular focus on drug development. Other major investment areas include medtech, digital health, life science tools and agri-biotech.

In Flanders, Gimv has already invested in several leading players from the local life sciences & health ecosystem, including biopharma innovator Ablynx. Want to discover the many other companies and organizations that make Flanders stand out in terms of life sciences & health? Head to Flanders360 or check out our industry overview.